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One of the most striking results in the area of chromatin
and cancer in recent years has been the identification of
recurrent mutations in histone genes in pediatric cancers.
These mutations occur at high frequency and lead to the
expression of mutant histones that exhibit oncogenic fea-
tures. Thus, they are termed oncohistones. Thus far, mu-
tations have been found in the genes encoding histone H3
and its variants. The expression of the oncohistones af-
fects the global chromatin landscape through mecha-
nisms that have just begun to be unraveled. In this
review, we provide an overview of histone mutations
that have been identified and discuss the possible mecha-
nisms by which they contribute to tumor development.
We further discuss the targeted therapies that have been
proposed to treat cancers expressing oncohistones.
Gene expression in eukaryotic cells is a highly regulated
process in which the binding of transcription factors and
the activity of the basic transcriptional machinery are
constrained and facilitated at the level of chromatin (for
recent reviews, see Voss and Hager 2013; Venkatesh
and Workman 2015; Buschbeck and Hake 2017). Chro-
matin, which consists of DNA and associated proteins,
is organized by nucleosomes. The nucleosome contains
DNA wrapped around an octamer containing four heter-
odimers of the core histone proteins H2A, H2B, H3, and
H4 (Fig. 1A). Higher-order chromatin also contains the
linker histone H1, which binds to linker DNA between
two nucleosomes and stabilizes the more compact chro-
matin. In addition to “canonical” histones, eukaryotic
cells also express histone variants that are incorporated
at specific genomic loci and provide another layer of
gene regulation.
Canonical histones comprise the majority of histones
in any given cell; are synthesized only during S phase,
where DNA replication takes place; and are therefore
termed “replication-coupled histones.” In contrast, his-
tone variants are expressed throughout the cell cycle
and are termed “replication-independent histones” (Fig.
1B). Canonical histones are the most abundant proteins
in all nucleated cells and are expressed from multiple
genes that are organized in gene clusters mostly located
on human chromosomes 1 and 6 (Buschbeck and Hake
2017). Expression of canonical histones from gene clusters
ensures the simultaneous expression of all the four core
histones to similar levels and the efficient organization
of newly replicated DNA into chromatin. Canonical his-
tone genes are intronless and contain a conserved palin-
dromic termination element instead of code for a polyA
tail, whereas histone variants often contain introns and
have polyA tails.
Histones carry a large number of post-translational
modifications, which are deposited and removed by spe-
cific enzymes. In addition, histones and nucleosomes
are subjected to remodeling by ATP-dependent chromatin
remodeling complexes. The combination of these events
impacts the chromatin state, making it permissible or re-
strictive to gene expression, and thus in turn plays an es-
sential part in determining cellular phenotypes. Given
the fundamental role of chromatin in regulating gene ex-
pression, many histone-modifying enzymes and chroma-
tin remodeling complexes have been found to be
essential for normal development, and their function is af-
fected in many diseases, including cancer (Albert and
Helin 2010; Kooistra and Helin 2012; Narlikar et al.
2013; Feinberg et al. 2016).
Pertinent questions
• Why are oncohistones restricted to certain types of
tumors and, in particular, pediatric tumors?
• Why do histone mutations occur in specific genes?
• What are the cells of origin for tumors harboring histone
mutations?
• Are there additional mutations giving rise to oncohistones
other than those identified so far?
• How do oncohistones affect global chromatin landscape
and contribute to tumor development?
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The role of chromatin in cancer has been further
strengthened by the recent discovery of mutations in his-
tone H3 genes in specific adolescent and pediatric tu-
mors. Mutations have been found in both the canonical
and variant forms of H3, involving amino acid residues
that are known substrates or are adjacent to substrates
of histone-modifying enzymes. The mutations in his-
tone-coding genes occur at very high frequencies in these
types of tumors, and, in some cases, the histone mutation
is found to be the only recurrent mutation identified in
the tumor, suggesting that the histone mutations act as
driver mutations. Furthermore, missense, rather than
nonsense, mutations occur at specific residues, indicating
that they are oncogenic mutations, and thus mutant his-
tones are termed as “oncohistones” (Schwartzentruber
et al. 2012; Behjati et al. 2013). So far, the mutations
have been found to occur in a single allele of one of the
multiple histone H3 genes in the tumor cell. Since there
are 15 different H3 genes, this indicates a highly domi-
nant nature of oncohistones. Interestingly, the amino
acid changes found in the histone H3 genes are highly
specific to the cancer type as well as to the anatomical lo-
cation of the tumor, suggesting that the transforming
ability of the oncohistones is dependent on the cell of
origin.
Histone H3 and its variants
H3.1 and H3.2 are the two canonical forms of H3 that
are expressed from 10 and three genes clustered on hu-
man chromosomes 6 and 1, respectively. There are six
replication-independent variants of H3: H3.3, centro-
mere protein A (CENP-A), H3.X, H3.Y, and two testis-
specific H3 variants (H3.1T and H3.5). Thus far, all of
the histone mutations found in cancer have been identi-
fied in either the canonical forms of H3 or in H3.3. The
relative abundance of H3.3 varies according to cell type
and the proliferation status of the cell. While H3.3 in
actively dividing cells constitutes up to 25% of total
H3, it makes up close to 90% of total H3 in terminally
differentiated neurons (Piña and Suau 1987). This is con-
sistent with the fact that H3.1 and H3.2 can only incor-
porate into the chromatin during DNA replication,
whereas, in nondividing cells, H3.3 continues to be in-
corporated and replaces H3.1 and H3.2 (Maze et al.
2015; Tvardovskiy et al. 2017).
The amino acid sequences of H3.1, H3.2, and H3.3 are
highly similar, with H3.1 and H3.2 differing in only a sin-
gle amino acid,whereasH3.3 differs fromH3.1 andH3.2 in
five and four amino acids, respectively (Fig. 1C). All except
one of these differences are found in the core histone fold
domain and provide specificity for different histone chap-
erones: While H3.1 and H3.2 are incorporated all over
the genome during DNA replication by CAF1 (chroma-
tin-associated factor 1), the incorporation of H3.3 is medi-
atedby two separate chaperones (HIRAandDAXX–ATRX)
and is enriched at distinct genomic regions (Fig. 1D;
Tagami et al. 2004; Drané et al. 2010; Goldberg et al.
2010). Remarkably, a single divergent residue, Gly90, in
H3.3 is required for the specific H3.3–DAXX interaction
(Elsässer et al. 2012). H3.3 is specifically enriched over
transcription start sites (TSSs) of both active and repressed
genes as well as over the body of active genes (Goldberg
et al. 2010). Additionally, H3.3 is enriched over regulatory
elements, including pericentric heterochromatin and telo-
meres (Drané et al. 2010; Goldberg et al. 2010). While en-
richment of H3.3 over genes is mediated by HIRA, the
ATRX–DAXX complex incorporates H3.3 at pericentric
heterochromatin and telomeres (Fig. 1D; Drané et al.
2010; Goldberg et al. 2010; Lewis et al. 2010; Wong et al.
2010).
H3.3 is expressed by two genes, H3F3A and H3F3B,
and, in contrast to canonical histones that are present
in clusters, H3F3A and H3F3B are located separately
on human chromosomes 1 and 17, respectively. Both
H3F3A and H3F3B are expressed ubiquitously but at var-
iable levels in different tissues (Jang et al. 2015). Genetic
studies in mice have shown that deletion of both H3F3A
and H3F3B leads to early embryonic lethality (Jang et al.
2015). Mice lacking eitherH3F3A or H3F3B have distinct
Figure 1. Nucleosomes, expression of H3 proteins, and their in-
corporation into nucleosomes. (A) Schematic diagram showing a
nucleosome, which consists of a histone octamer (containing two
copies each of H2A, H2B, H3, and H4) and 146 base pairs of DNA
wrapped around the octamer. (B) Expression of canonical (H3.1
and H3.2) and variant (H3.3) histone H3 during the cell cycle.
H3.1 andH3.2 are expressed only during the S phase of the cell cy-
cle, and their incorporation into the chromatin is coupled with
DNA replication, whereas H3.3 is expressed and incorporated
throughout the cell cycle independently of DNA replication.
(C ) Sequence alignment of H3.1, H3.2, and H3.3 proteins. Resi-
dues that are not conserved are shown in red, and the residues
that are found to bemutated in tumors are highlighted. (D) Differ-
ential incorporation of canonical and variant H3 into chromatin.
During S phase, H3.1 and H3.2 are deposited into chromatin
throughout the chromosome by CAF1 (chromatin-associated fac-
tor 1), while H3.3 is incorporated at distinct genomic loci by two
dedicated histone chaperons. The ATRX/DAXX complex medi-
ates the assembly of H3.3 at telomeres and pericentric hetero-
chromatin, while HIRA mediates the incorporation of H3.3 at
euchromatic regions, including promoters, gene bodies, and regu-
latory elements.
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phenotypes, and the severity of the phenotypes varies be-
tween different studies (Couldrey et al. 1999; Tang et al.
2013; Yuen et al. 2014; Jang et al. 2015). Since H3F3A
and H3F3B have identical amino acid sequences, the dif-
ferent phenotypes might reflect the difference in expres-
sion of the two genes during development (Jang et al.
2015).
Oncohistones
Histonemutations in cancer were first reported in histone
H3 genes encoding p.Lys27Met (K27M) or p.Gly34Arg/
Val (G34R/V) in pediatric high-grade gliomas (pHGGs)
(Khuong-Quang et al. 2012; Schwartzentruber et al. 2012;
Wu et al. 2012; Fontebasso et al. 2014; Taylor et al.
2014). Later, mutations in histone H3 genes encoding p.
Lys36Met (K36M) and p.Gly34Trp/Leu (G34W/L) were
found in chondroblastomas and giant cell tumors of bone
(GCTBs), respectively (Behjati et al. 2013). Chondroblasto-
mas are rare bone tumors affecting mostly children and
youngadults of <20yrof age (DeMattos et al. 2013),where-
asGCTBs are relatively commonbone tumors that are typ-
ically seen in early adulthood. The histone mutations
occur at very high frequency, and, in the case of diffuse in-
trinsic pontine gliomas (DIPGs), H3K27Mmutation is ob-
served across all of the anatomical regions in the primary
and metastatic tumor sites analyzed, including radiologi-
cally and histologically normal areas, suggesting that
H3K27M mutation is the initial oncogenic event (Hoff-
man et al. 2016; Nikbakht et al. 2016). Moreover,
H3K27M mutation is maintained throughout the course
of the disease, from diagnosis to the end stage, suggesting
that H3K27M is required for tumor maintenaince (Nik-
bakht et al. 2016).
Strikingly, all of the driver histone mutations are found
in the tumors of children or young adults. Thus, even
though adult HGGs are histologically very similar to
pHGGs, K27M and G34R/V mutations are rarely found
in adult HGGs, suggesting that the impact of histone mu-
tations in cancer initiation and progression is limited to
specific developmental settings.
One of the remarkable features of histone mutations is
that these mutations are highly tumor type-specific and
restricted to defined anatomical locations. For example,
K27M and G34R/V mutations are mutually exclusive
and restricted to specific locations in the central nervous
system (CNS). K27M mutations are restricted to midline
(thalamus, cerebellum, spine, and pons) tumors with the
highest frequency (up to 93%) (Fontebasso et al. 2014)
found inDIPGs, an aggressive and diffusely infiltrating tu-
mor located in the pons (Mackay et al. 2017). In contrast,
G34R/Vmutations are found exclusively in pHGGs of ce-
rebral cortex with the frequency of 14%–15% (Fig. 2; Ta-
ble 1). The restricted occurrence of K27M and G34R/V
mutations to specific anatomical sites suggests a distinct
cell of origin for midline and cortical pediatric tumors as
compared with adult brain tumors.
Another feature of histonemutations is that they prefer-
entially affect a specific histone H3 variant. The majority
of histone mutations found in cancer occurs in the H3.3
variant, except for the K27M mutation, which has also
been found in canonical H3.1 and H3.2, albeit with lower
frequency. We still do not understand the significance of
the preferential prevalence of histone mutations in the
H3.3 variant. While H3.1 and H3.2 are incorporated into
nucleosomes throughout the genome with no specificity,
H3.3 is enriched at discrete genomic regions, including
active genes, regulatory elements, pericentric heterochro-
matin, and telomeres (Goldberg et al. 2010). Thus, muta-
tion in canonical and variant histones may well have
distinct effects on the cellular phenotype. Consistent
with this, tumors harboring K27M mutations in H3.1
and H3.3 are clinically and molecularly distinct.
H3.1K27M tumors occur in younger patients and are re-
stricted to the pons, and these patients show better prog-
nosis than patients with H3.3K27M-positive tumors
(Fontebasso et al. 2014; Taylor et al. 2014; Wu et al.
2014; Castel et al. 2015). Moreover, H3.1K27M and
H3.3K27M tumors show distinct gene expression profiles.
Gene expression inH3.1K27M tumors is similar to the ex-
pression profiles in adult tumors with a mesenchymal/as-
trocytic phenotype, whereas H3.3K27M tumors are more
similar to tumors with a proneural/oligodendroglial
phenotype (Castel et al. 2015). Last, H3.1K27M and
H3.3K27M mutant tumors have distinct cosegregating
mutations. For example, mutations in Activin A receptor
type 1 (ACVR1) and BCL6 corepressor (BCOR) genes cose-
gregate with H3.1K27M mutation, while platelet-derived
growth factor receptor α (PDGFRA) and DNA topoisomer-
ase III α (TOP3A) amplification and TP53 mutation cose-
gregate with H3.3K27M mutation (Taylor et al. 2014;
Wu et al. 2014; Mackay et al. 2017).
Although canonical and variant forms of H3 are ex-
pressed by multiple genes, mutations in histones occur
only in specific genes (Table 2). For example, among the
two genes encoding H3.3, K27M and G34R/V mutations
occur exclusively in H3F3A, whereas the majority of
K27M mutation in H3.1 occurs in HIST1H3B (one of the
10 H3.1 genes). However, rare mutations in HIST1H3C
Figure 2. Differentmutations in histone H3 are found in tumors
located in distinct anatomical locations. Depicted here is the oc-
currence of G34R/V and K27Mmutations in different anatomical
regions in the brain. G34R/Vmutants are restricted to the tumors
located in cerebral cortex, while the K27Mmutant is found only
in tumors of the midline structure (including the thalamus, cere-
bellum, brain stem, spine, and fourth ventricle).
Oncohistones: drivers of pediatric cancers
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(H3.1) andHIST2H3C (H3.2) have also been found in mid-
line tumors (Fontebasso et al. 2014; Castel et al. 2015).
This specificity can be explained partially by the fact that
Lys27 in H3F3A and H3F3B is encoded by “AAG” and
“AAA,” respectively. Thus, mutation of Lys27 tomethio-
nine (coded by “ATG”) in H3F3Awould require substitu-
tion of only one residue, while two residues need to be
mutated in H3F3B. However, this does not explain why
the majority of H3.1K27M mutations occurs in the
HIST1H3B gene, since Lys27 is encoded by “AAG” in six
out of 10 genes expressing H3.1, including HIST1H3B.
Similarly, the preferential occurrence of G34R/V or
G34W/L mutation in H3F3A or K36M mutation in
H3F3Bcannotbeexplainedby thecodonsequencebecause
Gly34 and Lys36 are encoded by identical codons in
H3F3A and H3F3B. The specificity of histone mutations
to different genes might reflect the differential expression
of histone genes in different tissues (Krimer et al. 1993;
Bramlageet al. 1997; Jang et al. 2015).H3F3Ahasmoreuni-
form expression across different tissues, whereas H3F3B
shows more restricted expression (Krimer et al. 1993;
Bramlage et al. 1997; Jang et al. 2015). Although H3F3A
and H3F3B mRNAs code for identical proteins, they have
very different 5′ and 3′ UTRs (untranslated regions).
Thus, H3F3A and H3F3B mRNAs could be subject to dif-
ferent post-transcriptional regulation such as by micro-
RNA, which would further lead to differential
contributions of the H3F3A and H3F3B genes to total
H3.3 in different tissues. Estimating the contribution of
H3F3A andH3F3B to total H3.3 protein at different devel-
opmental stages and in different tissues might help in un-
derstanding the biased occurrence of histonemutations in
different H3.3 genes.
The three amino acids (K27, K36, and G34) that are
found as mutants in tumors lie within the unstructured
N-terminal tail of histone H3. This region contains
many different types of post-translational modifications,
which are involved in regulating different biological pro-
cesses, including gene expression, nuclear organization,
DNA repair, and DNA replication (Kouzarides 2007). In
Table 2. Codon sequences of amino acid residues of human histone H3 and its variants that are found to be mutated in tumors
Gene Chromosome K27(M) K27(I) K36(M) G34(R) G34(V) G34(W) G34(L)
H3.3
H3F3A 1 AAG AAG AAG GGG GGG GGG GGG
H3F3B 17 AAA AAG AAG GGG GGG GGG GGG
H3.1
HIST1H3A 6 AAA AAA AAA GGC GGC GGC GGC
HIST1H3B 6 AAG AAG AAA GGC GGC GGC GGC
HIST1H3C 6 AAG AAG AAG GGC GGC GGC GGC
HIST1H3D 6 AAG AAG AAG GGC GGC GGC GGC
HIST1H3E 6 AAG AAG AAG GGC GGC GGC GGC
HIST1H3F 6 AAA AAA AAG GGC GGC GGC GGC
HIST1H3G 6 AAA AAA AAG GGC GGC GGC GGC
HIST1H3H 6 AAG AAG AAG GGT GGT GGT GGT
HIST1H3I 6 AAG AAG AAG GGC GGC GGC GGC
HIST1H3J 6 AAA AAA AAG GGT GGT GGT GGT
H3.2
HIST2H3C 1 AAG AAG AAG GGG GGG GGG GGG
HIST2H3D 1 AAG AAG AAG GGG GGG GGG GGG
HIST2H3A 1 AAG AAG AAG GGG GGG GGG GGG
Alleles that are found to be mutated in cancer are shaded green. Nucleic acids that need to be mutated to convert the respective
amino acid residue to the one indicated in the parentheses are indicated in red.
Table 1. Histone mutations identified in pediatric tumors
Tumor Mutation Histone subtype Affected gene Frequency Codon wild type (mutated)
DIPG K27M H3.3 H3F3A Up to 93% AAG (ATG)
H3.1 HIST1H3B Up to 31% AAG (ATG)
HIST1H3C <3% AAG (ATG)
H3.2 HIST2H3C <2% AAG (ATG)
K27I H3.3 H3F3A <1% AAG (ATT)
Non-DIPG pHGG G34R H3.3 H3F3A 12%–14% GGG (CGG/AGG)
G34V H3.3 H3F3A <2% GGG (GTG)
GCTB G34W H3.3 H3F3A 92% GGG (TGG)
G34L H3.3 H3F3A <2% GGG (TTG/CTG)
Chondroblastoma K36M H3.3 H3F3B 88% AAG (ATG)
H3F3A 7% AAG (ATG)
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the following sections, we discuss how the known histone
mutantsmay contribute to tumorigenesis through disrup-
tion of normal H3 modification patterns and cellular
functions.
H3K27M mutation in pHGGs
H3K27 can be monomethylated (H3K27me1), dimethy-
lated (H3K27me2), and trimethylated (H3K27me3) as
well as acetylated (H3K27ac). Methylation of K27 is cata-
lyzed by Polycomb-repressive complex 2 (PRC2), a multi-
protein complex with three core components: enhancer
of zeste homolog 1 (EZH1) or EZH2 (catalytic subunit),
suppressor of zeste 12 (SUZ12), and embryonic ectoderm
development (EED) (Di Croce and Helin 2013). They are
members of the Polycomb group (PcG) protein family
and work together with the functionally related PRC1
complex to maintain gene repression. PRC2 can have
both oncogenic and tumor-suppressing functions, and
both activating and loss-of-function mutations in PRC2
genes are frequently found in various cancers (Comet
et al. 2016).
pHGGs, including DIPGs, expressing mutant H3K27M
display globally reduced H3K27me3 and increased
H3K27ac levels (Bender et al. 2013; Lewis et al. 2013; Ven-
neti et al. 2013). The global effect of H3K27M on chroma-
tin is surprising given the fact that the histone H3.1/3
K27Mis expressed fromasingle allele, and themutantpro-
tein therefore constitutes only a small fraction (3.63%–
17.61%) of total H3 in the tumor cells (Lewis et al. 2013).
This suggests a strong dominant effect of H3K27M over
wild-type H3. The dominant effect of H3.1K27M is even
more remarkable considering that H3.1 is incorporated
into chromatin only during DNA replication and that
H3.1K27M is expressed from one single allele of a total
of 20 different H3.1 alleles.
Exogenous expression of H3.3K27M or H3.1K27M in
mouse and human cells results in global reduction in
H3K27me2/3 levels (Bender et al. 2013; Chan et al.
2013; Lewis et al. 2013; Funato et al. 2014; Mohammad
et al. 2017). Interestingly, comprehensive testing of vari-
ous H3K27 mutant proteins has shown that the global
decrease in H3K27me2/3 levels is specific to K27M and,
to a lesser extent, K27I (Lewis et al. 2013). Consistent
with this, a rare K27I mutation, which is also associated
with reduced H3K27me3 levels, has been identified in
DIPGs (Castel et al. 2015). Substitution of K27 with any
other amino acid residue does not lead to a global reduc-
tion in H3K27me3 levels (Lewis et al. 2013), indicating
the remarkable specificity of K27M/I mutations. The ex-
clusive finding of K27M/K27I mutants indicates a causal
role of the global effect on H3K27 methylation.
Although a reduction in H3K27me3 levels is a hallmark
of pHGGs expressing H3K27M, genome-wide analyses of
H3K27me3 show significant locus-specific enrichment of
H3K27me3 in H3K27M tumor cells (Bender et al. 2013;
Chan et al. 2013). Interestingly, the regions that remain
enriched for H3K27me3 in H3K27M cells span larger
chromatin domains and have higher H3K27me3 density
when compared with wild-type cells, indicating signifi-
cant PRC2 activity in H3K27M cells (Chan et al. 2013).
Locus-specific changes in H3K27me3 caused by
H3K27M have also been analyzed in DIPG models,
where wild-type or K27M mutant H3.3 was exogenously
expressed in isogenic cells. Funato et al. (2014) described
a DIPG model in which exogenous expression of
H3.3K27M along with overexpression of PDGFRA and
p53 knockdown transformed human embryonic stem
cell (ESC)-derived neural stem cells (NSCs) and led to the
resettingofNSCsto amoreprimitive stemcell state. Inter-
estingly, the transforming ability ofH3.3K27Mwas highly
cell type-specific, as expression ofH3.3K27M in differenti-
ated somatic cells such as astrocytes or fibroblasts led to
senescence (Funato et al. 2014). Compared with NSCs ex-
pressing wild-type H3.3, NSCs expressing H3.3K27M
showed genomic redistribution of H3K27me3 with both
loss and gain of gene-specific H3K27me3 (Funato et al.
2014).
Recently, we described a DIPG model in which coex-
pression of H3.3K27M and PDGFB in mouse NSCs lead
to tumor development in immunodefficient mice (Mo-
hammad et al. 2017). Analysis of the genomic distribution
of H3K27me3 showed that it was lost or reduced at the
majority of genomic loci and unaffected at a significant
number of loci. Interestingly, a few loci showed increased
H3K27me3 levels in H3.3K27M-expressing cells when
compared with cells expressing wild-type H3.3. The dis-
tribution of H3K27me3 in mouse NSCs expressing
H3.3K27M was significantly overlapping with the
H3K27me3 profile in human H3K27M mutant DIPG
cell lines. Interestingly, therewas a very strong correlation
between the initial H3K27me3 enrichment in wild-type
NSCs and the effect of H3K27M expression. Loci with
low initial H3K27me3/PRC2 enrichment showed a com-
plete loss of or reduced H3K27me3, while loci with high
initial H3K27me3/PRC2 enrichment showed no change
in H3K27me3 levels. However, loci with increased
H3K27me3 in H3K27M cells showed no apparent correla-
tion with the initial H3K27me3. Thus, themajority of dif-
ferential effects of H3K27M on different genomic loci can
be explained by the level of PRC2 activity (Mohammad
et al. 2017).
The cyclin-dependent kinase inhibitor 2a (Cdkn2a) lo-
cus, coding for the p19Arf and p16Ink4a (p16) tumor sup-
pressor proteins, was one of the loci with increased
H3K27me3 in H3K27M cells. The increased H3K27me3
levels at the Cdkn2a locus was associated with reduced
expression of p16 in H3K27M cells. Consistent with
this, DIPG cell lines harboring the H3K27M mutant also
showed high H3K27me3 levels at the CDKN2A locus
and, correspondingly, very low p16 expression (Moham-
mad et al. 2017). Homozygous deletion of the CDKN2A
locus is very frequent (>55%) in adult HGGs (Brennan
et al. 2013) but rarely found in pHGGs (Mackay et al.
2017). Thus, H3K27M-mediated repression of the
CDKN2A locus likely reflects an alternative approach to
silence the CDKN2A locus in pHGGs. In addition to the
effect on the CDKN2A locus, cells expressing H3K27M
show expression changes in several other genes, including
Oncohistones: drivers of pediatric cancers
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potential oncogenes and tumor suppressor genes when
compared with cells expressing wild-type H3. The contri-
bution of these genes to the development of H3K27M tu-
mors is currently not known.
How the expression of H3K27M can lead to increased
H3K27me3 at specific loci is not yet completely un-
derstood. Since the association of H3K27M with a
locus should lead to a reduction and not an increase
of H3K27me3 at the locus, the increased levels of
H3K27me3 at specific loci are most likely occurring
through a selection process in which the cell of origin for
DIPGs already has high levels of H3K27me3 associated
with these loci, which are maintained and/or selected for
during the development of the tumor. Importantly, howev-
er, it is also not yet clear whether the global changes in
H3K27me3 enrichment observed in H3K27M tumors are
the cause or the consequence of cellular transformation.
One of the caveats of DIPG models described so far is
that they are made without prior knowledge regarding
the cell of origin for DIPGs, which is yet unknown. Candi-
dates for the cell of origin for DIPGs include precursor
cells in the ventral pons (Nestin+/Vimentin+/Olig2+)
(Monje et al. 2011) or the fourth ventricle floor (Nestin+/
Pax3+) (Misuraca et al. 2016). Despite this, the NSC-based
DIPGmodels show features similar to patient tumors and
have provided useful mechanistic insights. H3K27M-driv-
en tumors in these models show gene expression profiles
overlapping with H3K27M patient tumors (Funato et al.
2014; Mohammad et al. 2017). Moreover, NSCs express-
ing H3K27M show H3K27me3 enrichment profiles simi-
lar to patient-derived DIPG cell lines (Mohammad et al.
2017).
Recently, an in utero DIPGmodel has been described in
which expression of H3.3K27M along with the loss of p53
in the hindbrain and the cortex of mouse embryos lead to
the development of serially transplantable diffuse tumors
(Pathania et al. 2017). H3.3K27M can induce tumorigene-
sis only during a specific stage of development, as expres-
sion of H3.3K27M was lethal during post-zygotic embryo
development, whereas its expression in the postnatal
mouse brain failed to induce tumors. Interestingly, ex-
pression of H3.3K27M fromNestin (Nes) or glial fibrillary
acidic protein (Gfap) promoters that are active in embry-
onic and postnatal NSCs also did not lead to tumor devel-
opment, and thus the cell of origin for H3K27M tumors
remains elusive.
The mechanistic basis for the global loss of H3K27me3
upon expression of H3K27M is incompletely understood.
Several results have suggested that the H3K27M histone
tail directly interferes with PRC2 activity. For instance,
in vitro studies show that an H3K27Mmutant peptide in-
hibits PRC2 activity through interactionwith its catalytic
subunit, EZH2, by competing with the substrate (Lewis
et al. 2013; Brown et al. 2014). However, it is interesting
to note that the modes of inhibition of PRC2 by
H3K27Mand currently available smallmolecule PRC2 in-
hibitors, which act by competing with the SAM cofactor
for binding toEZH2, are very different, and smallmolecule
PRC2 inhibitors do not induce molecular and phenotypic
effects similar to H3K27M (Mohammad et al. 2017).
Themode of interaction of H3K27Mwith PRC2was re-
solved by crystal structures of human and fungal PRC2 in
a complex with the H3K27M peptide, showing tight bind-
ing of H3K27M to the catalytic site of EZH2 (Jiao and Liu
2015; Justin et al. 2016). Compared with the wild-type H3
peptide, the H3K27M peptide binds PRC2 with 16-fold
higher affinity (Justin et al. 2016). Based on these observa-
tions, it has been proposed that strong binding of PRC2 to
H3K27M mutant histones at the chromatin leads to
sequestration and inactivation of PRC2 at H3K27M-con-
taining nucleosomes, thereby leading to global reduction
of H3K27me3 levels (Fig. 3A). However, several
Figure 3. Proposed mechanisms by which
oncohistones affect the activity of histone
methyltransferases (HMTs). (A) K-to-M mu-
tant histones bindmore tightly to the catalytic
site within the SET domain of HMTs than
wild-type histones, leading to sequestration
of the HMT complex to mutant nucleosomes
and rendering the HMT nonproductive due to
the absence of the substrate. (B) The G34 resi-
due of histone H3 is buried in a narrow tunnel
within the active site of SETD2. Mutation of
G34 to residues with a larger side chain (R/V/
W/L) might result in distortion of the catalytic
site that would render SETD2 inactive.
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laboratories have analyzed the interaction between
H3K27M and PRC2 using various assays, including im-
munoprecipitation and electrophoretic mobility shift as-
say (EMSA), and have reached different conclusions.
Some studies (Bender et al. 2013; Chan et al. 2013; Justin
et al. 2016) have shown a tighter interaction between
PRC2 and H3K27M as compared with wild-type H3,
whereas other studies (Herz et al. 2014; Wang et al.
2017) have not observed the same. The reason for these
different results is not clear.
In potential contrast to the sequestration model, recent
results suggest that H3.3K27M is enriched specifically in
actively transcribed regions of the genome and that PRC2
is precluded from these regions (Piunti et al. 2017). These
results would be in line with the fact that H3.3 shows sig-
nificantly higher enrichment over the bodies of active
genes (Goldberg et al. 2010). Thus, reduced enrichment
of H3.3K27M over the repressed genes that are strong
PRC2 targets might explain the retained H3K27me3 lev-
els over these genes in H3.3K27M tumors. However,
this reasoning does not explain the retained gene-specific
H3K27me3 in cells expressing H3.1K27M, considering
that H3.1 and H3.2 are uniformly distributed over the ge-
nome (Goldberg et al. 2010). Taken together, the available
results show that H3K27M inhibits PRC2 in vitro; howev-
er, H3K27M expression does not lead to complete loss of
PRC2 activity in vivo, and further studies are required to
elucidate whether differential enrichment of H3K27M is
responsible for residual PRC2 activity in the tumor cells.
The H3K36M mutant in chondroblastomas
Mutations in H3 genes leading to the expression of
H3K36M have been identified with high frequency
(∼95%) in chondroblastomas (Behjati et al. 2013). Thema-
jority ofK36Mmutations occurs in theH3F3B gene encod-
ing H3.3 (Behjati et al. 2013). The K36 residue on histone
H3 can be monomethylated (H3K36me1), dimethylated
(H3K36me2), or trimethylated (H3K36me3). Inmammals,
several histone methyltransferases (HMTs) catalyze
H3K36 methylation. Nuclear receptor SET domain-con-
taining 1 (NSD1), NSD2, NSD3, and ASH1-like (ASH1L)
are the main enzymes that catalyze monomethylation
and dimethylation of H3K36, whereas SETD2 is the
only known enzyme that catalyzes the conversion of
H3K36me2 to H3K36me3 (Wagner and Carpenter 2012).
H3K36me2 and H3K36me3 are enriched over the gene
bodies of transcriptionally active genes, where they are re-
quired for the repression of aberrant transcriptional initia-
tion within coding sequences (Carrozza et al. 2005). In
addition, H3K36me2 and H3K36me3 have been shown
to play important roles in DNA repair, dosage compensa-
tion, and splicing (Wagner and Carpenter 2012). Similar
to H3K27Mmutation in pHGGs, H3K36Mmutant chon-
droblastomas show global loss of H3K36me2/3 (Fang
et al. 2016; Lu et al. 2016). The K36M peptide or K36M
mononucleosomes inhibit NSD2 and SETD2 with no ef-
fect on NSD1 and ASH1L (Fang et al. 2016; Lu et al.
2016). Ectopic expression of H3.3K36M in mesenchymal
progenitor cells (MPCs) blocks the differentiation of
MPCs into different lineages, including chondrocytes, ad-
ipocytes, and osteocytes (Lu et al. 2016), and MPCs
expressing H3.3K36M generate sarcomas when trans-
planted into immunodefficientmice (Luet al. 2016).These
results demonstrate that H3K36M can be a driving onco-
protein in MPCs.
Genome-wide enrichment analysis has shown that ec-
topic expression of H3K36M leads to a global reduction
of H3K36me2/3 in MPCs, with the strongest effect ob-
served on H3K36me2 (Lu et al. 2016). H3K36me2 was
completely lost at the intergenic loci, while it was signifi-
cantly reduced at the genic regions in H3K36M cells.
Moreover, H3K36M-expressing cells showed significantly
reduced H3K36me3 enrichment over gene bodies, which
was associated with gene expression changes (Lu et al.
2016). Similar results were obtained in human immortal-
ized chondrocytes harboring a H3K36M mutation in the
endogenous H3F3B gene (Fang et al. 2016). The genome-
wide distribution of H3K36M histones has been analyzed
in primary cells expressing H3K36M by immunoprecipi-
tating tagged histones or using an H3K36M-specific anti-
body (Fang et al. 2016; Lu et al. 2016). The distribution of
histone H3 was found to be unaffected by the H3K36M
mutation, suggesting that the mutation does not affect
how nucleosomes are positioned.
Interestingly, Lu et al. (2016) observed a global increase
in H3K27me3 in primary cells expressing H3K36M as
well as inH3K36Mmutant chondroblastomas, suggesting
that the loss of H3K36 methylation provides a new nucle-
osomal substrate for PRC2. This is consistent with previ-
ous observations showing that PRC2 activity is inhibited
by H3K36 methylation (Schmitges et al. 2011; Yuan et al.
2011). The increasedH3K27me3 inH3K36M cells was ob-
served primarily in the intergenic regions and was associ-
ated with a decrease in PRC1 enrichment in the genic
regions. Based on these observations, Lu et al. (2016) pro-
posed that an increase in H3K27me3 at the intergenic re-
gions inH3K36M cells leads to redistribution and dilution
of PRC1 in genic regions. A similar model has been pro-
posed to explain chromatin changes inmultiplemyeloma,
where increased activity of NSD2 results in a global in-
crease in H3K36me2 levels and a concurrent decrease in
H3K27me3 levels (Popovic et al. 2014). In contrast to
the report by Lu et al. (2016), another study did not ob-
serve increased H3K27me3 in human chondrocytes ex-
pressing H3K36M (Fang et al. 2016). At present, the
reason for these contrasting observations is not clear.
A recent crystal structure shows that H3K36M binds
strongly to the catalytic site of SETD2 (Yang et al. 2016;
Zhang et al. 2017). Based on this, a model similar to the
one discussed for H3K27M-mediated inhibition of PRC2
has been proposed, in which H3K36M mutant nucleo-
somes strongly bind and sequesterH3K36methyltransfer-
ases (Fig. 3A). However, it is not clear why H3K36M
inhibits only NSD2 and SETD2 but not NSD1 even
though residues interacting with H3K36M are highly con-
served in these H3K36 methyltransferases. Moreover,
similar to NSD2 and SETD2, NSD1 also preferentially as-
sociates with H3K36M nucleosomes (Lu et al. 2016),
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indicating that mechanisms other than sequestering of
methyltransferasesmight be involved. Structural compar-
ison of NSD1 and NSD2 bound to K36M could provide
more insight into the differences.
H3G34 mutants in pHGGs and GCTB
One of the most interesting observations regarding the
H3G34 oncohistone mutants is the fact that the G34R/V
mutant is specifically found in pHGGs located in the cere-
bral cortex, while the G34W/L mutant is specifically
found in GCTB. pHGGs harboring the G34R/V mutant
are clinically and biologically distinct from H3K27Mmu-
tantDIPGs.H3G34mutant pHGGs showbetter prognosis
and occur in patients with a higher median age than
H3K27M tumors (Schwartzentruber et al. 2012; Sturm
et al. 2012; Wu et al. 2012). H3G34 mutant pHGGs show
reduced levels of DNA methylation, which is more
prominent at telomeric regions (Sturm et al. 2012). This
observation is consistent with the frequently observed al-
ternative lengthening of telomeres (ALT) in H3G34 mu-
tant pHGGs (Schwartzentruber et al. 2012). The Gly34
residue of H3 has not yet been shown to be associated
with any modification, and, unlike the H3K27Mmutant,
the H3G34R/V mutant has not been shown to change
the global post-translationalmodification level of anyami-
no acid onH3.However,G34 is located close toK36 on the
H3 tail, and ectopic expression of H3.3G34R/V leads to
reduced H3K36me2 and H3K36me3 levels on mutant
nucleosomes, with no effect on nucleosomes containing
wild-type histones, suggesting that, unlike H3K27M,
H3G34R/V does not act as a dominant-negative mutant
(Lewis et al. 2013).
Crystallographic studies of the SET domain of SETD2
bound to an H3K36M peptide have provided insights
into the molecular mechanisms by which H3G34 mu-
tants can affect H3K36 methylation. The H3G34 residue
is buried deep in the SET domain in a very narrow tunnel
with no space to accommodate residues with large side
chains (Zhang et al. 2017). In agreement with this, the in-
troduction of mutations in G34 in one of the endogenous
H3 genes in fission yeast—leading to the expression of on-
cogenic R, V, L, or W residues or other residues with lon-
ger side chains (A, C, S, D, N, and T)—has been shown to
affect H3K36me3 on the mutant histone H3, most likely
by affecting the conformation of the SET domain of
SETD2 (Fig. 3B; Zhang et al. 2017). These results suggest
that the effect of H3G34R/V or H3G34W/L mutants on
H3K36me3 is not specific and can bemimicked by several
other H3G34 mutants. The reason why H3G34 mutants
identified in tumors are limited to specific residues may
therefore be explained by the codon sequence: In the
H3F3A gene, H3G34 is coded by “GGG,” and mutation
of single nucleic acids can convert it to Arg/R (“AGG”
and “CGG”), Trp/W (“TGG”), Val/V (“GTG”), Glu/E
(“GAG”), and Ala/A (“GCG”), while two or more nucleic
acid residues need to bemutated to convert H3G34 to any
other amino acid residue. This also explains why the
H3G34R mutant is more frequent than the H3G34V mu-
tant in pHGGs andwhy theH3G34Lmutant, identified in
only one sample of GCTB, is so rare. However, this does
not explain why the H3G34R/V and H3G34W/L mutants
are present only in pHGGs and GCTB, respectively, or
why the H3G34E and H3G34A mutants have not yet
been identified in pHGGs or GCTB. These observations
suggest that the H3G34 mutants do more than just affect
H3K36me2/3. Indeed, the H3G34R/V mutant has also
been shown to impair specific binding of ZMYND11, a tu-
mor suppressor, to H3.3K36me3 (Wen et al. 2014).Wheth-
er H3G34W/L similarly affects ZMYND11 binding and
how interference in chromatin binding of factors such as
ZMYND11 by H3G34 mutations would contribute to tu-
morigenesis are some of the open questions.
Thus far, only a few reports have been published on the
biological effects of H3G34 mutant expression. Ectopic
expression of H3.3G34V in normal human astrocytes or
transformed human fetal glial cells has been shown to re-
sult in increased MYCN expression, which was corrobo-
rated by expression analysis of H3G34 mutant pHGGs
(Bjerke et al. 2013). The effects of H3G34R expression
have been studied in fission yeast, where H3G34R expres-
sion from the only H3 gene led to a global decrease in
H3K36me3 and H3K36ac without detectable effects on
H3K36me2 (Yadav et al. 2017). Consistent with the role
of H3K36me3 in DNA repair, H3G34R mutant fission
yeast showed genomic instability and defects in DNA re-
pair (Yadav et al. 2017). However, these results were ob-
tained in an organism engineered to express only
mutant H3, which is in contrast to tumors where just
one out of four H3.3 alleles is mutated. Thus, these mech-
anismswill need to be investigated in amore relevant sys-
tem, where the correlation between the biological effects
of H3G34 mutants with locus-specific changes in
H3K36me2/3 enrichment can also be analyzed.
Targeted epigenetic therapies for oncohistone-expressing
tumors
The fact that the majority of pHGGs harbors histone mu-
tations that lead to alterations in the chromatin landscape
of tumor cells has prompted several investigators to test
the efficacy of different epigenetic therapies. In an attempt
to reverse the reduced H3K27me3 levels observed in
H3K27M tumors, Hashizume et al. (2014) analyzed the ef-
fect of inhibiting the H3K27me3 demethylases in
H3K27M mutant pHGGs. Inhibition of H3K27me3 his-
tone demethylases JMJD3 (KDM6B) and UTX (KDM6A)
by GSK-J4 resulted in increased H3K27me3 in H3K27M
mutant cell lines and showed in vitro and in vivo anti-tu-
mor activity (Hashizume et al. 2014). Interestingly, GSK-
J4 showed anti-tumor activity specifically against pHGGs
expressingH3K27M,with no significant effect on cells ex-
pressing wild-type or G34V mutant H3. The mechanism
by which GSK-J4 would be able to rescue the reduced
H3K27me3 in H3K27M cells is not clear, considering
that the tumor cells continue to express H3K27M. It is
also not clear whether the effect of GSK-J4 on tumor cells
is mediated by changes in H3K27me3 level particularly,
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since GSK-J4 can also inhibit the activity of other histone
demethylases (Heinemann et al. 2014).
In another study, Grasso et al. (2015) performed a chem-
ical screen on DIPG cell lines and identified panobinostat
as a drug that strongly affects in vitro and in vivo tumor
cell growth. Panobinostat is a nonselective histone deace-
tylase (HDAC) inhibitor that has been approved for the
treatment of multiple myeloma. Interestingly, along
with the increase in the level of acetylated histone H3,
panobinostat treatment of H3K27MDIPG cells also leads
to an increase in H3K27me3 levels and thus the partial
rescue of H3K27M-induced decrease in H3K27me3. This
is consistent with the previous observation that acetyla-
tion of lysine residues in the N-terminal tail of H3 coun-
teracts the PRC2 inhibitory effect of H3K27M (Brown
et al. 2014). Mechanistically, the use of panobinostat in
H3K27M mutant pHGGs appears counterintuitive, con-
sidering that H3K27M mutant pHGGs show increased
acetylation of H3K27, a histone mark associated with ac-
tive chromatin (Lewis et al. 2013; Piunti et al. 2017). It is
not clear how panobinostat treatment affects the
H3K27ac levels in H3K27M mutant tumors, and thus
the mechanism by which panobinostat affects tumor
growth remains unknown. Considering that panobinostat
inhibits multiple HDACs and that each HDAC can have
multiple histone and nonhistone targets (Yang and Seto
2008), identification of targets that mediate the effects
of panobinostat on tumor cells will be challenging.
The increased H3K27ac levels in H3K27M mutant
pHGGs lead to increased association of bromodomain-
containing proteins (BRD2 and BRD4), which bind to acet-
ylated histones (Herz et al. 2014; Piunti et al. 2017). This
observation led Piunti et al. (2017) to show that an inhib-
itor of bromodomain and extraterminal domain (BET)
family members, including BRD2 and BRD4, affects the
growth of H3K27M mutant cells.
Despite the global loss of H3K27me3, H3K27Mmutant
cells show significant residual PRC2 activity. The genes
that remain associated with H3K27me3 in H3K27M cells
are classical Polycomb targets whose transcriptional regu-
lation is crucial for cell fate decisions during develop-
ment, suggesting that their repression is required to
maintain cellular identity (Mohammad et al. 2017). Con-
sistent with this, inhibiting PRC2 activity in H3K27M
cells through EZH2 inhibition or genetic deletion of
EZH2 strongly affects tumor cell growth (Mohammad
et al. 2017; Piunti et al. 2017). Interestingly, reduced cell
proliferation induced by EZH2 inhibition is mediated by
p16, whose expression is significantly increased upon
EZH2 inhibitor treatment. Moreover, deletion of p16 in
a DIPG cell line renders tumor cells insensitive to EZH2
inhibition, suggesting that in DIPGs, p16 is the primary
target of PRC2 inhibitors (Mohammad et al. 2017). p16 in-
hibits CDK4 and CDK6, which in turn results in activa-
tion of pRB and cellular growth arrest. Considering that
DIPG cells are sensitive to high p16 levels, these cells
might also respond to CDK4/6 inhibitors. Given that
that several CDK4/6 inhibitors have already been ap-
proved for the treatment of advanced breast cancer,
CDK4/6 inhibition could be a viable alternative for the
treatment of DIPGs. Indeed, several clinical trials are un-
der way to test the efficacy of CDK4/6 inhibitors in pedi-
atric CNS tumors, including DIPGs.
Perspectives
The role of epigenetic regulators and chromatin-associat-
ed proteins in tumor etiology has been increasingly appre-
ciated, especially in the last decade, with frequent
mutations in the genes encoding epigenetic factors being
discovered in almost every cancer type. The discovery of
highly recurrent mutations in histone genes affecting
the global chromatin landscape in pediatric tumors has
further reinforced the role of epigenetic changes in tumor
development.Mechanistic details of oncohistone-mediat-
ed molecular changes in tumor cells have just started to
emerge, and these observations may lead to the develop-
ment of therapeutic strategies, especially for H3K27M
mutant pHGGs. K-to-M mutants of H3 act as dominant
mutants, and their expression leads to global changes in
the histonemodification levels in the tumor cells, primar-
ily through inhibition of specific HMTs. It is noteworthy
that K-to-M mutant cells display significant residual ac-
tivity of inhibited HMTs, indicating that the inhibition
of HMTs by K-to-M mutant H3 is not absolute. In some
cases, complete inhibition of the HMT is deleterious for
the K-to-M mutant tumor cells (Mohammad et al. 2017).
Moreover, no loss-of-function mutation in the inhibited
HMTs has been identified in pediatric tumors, and phar-
macological inhibition ofHMTdoes notmimic the effects
of K-to-Mmutation (Mohammad et al. 2017). These obser-
vations indicate that the simple inhibition of HMTs can-
not explain the molecular effects of K-to-M mutations in
H3, and future studies will be required to determine the
actual mode of inhibition of HMTs by K-to-M mutants.
Additionally, an understanding of how mutation in ca-
nonical or variant histone H3 leads to distinct molecular
profile in tumors will have potential implications in de-
veloping targeted therapies.
Mutations in histones are limited to specific genes even
though histone H3 and its variants are expressed from
multiple genes. This specificity of histone mutations
might be due to differential expression of histone H3
from individual genes in the tumor cell of origin. Muta-
tions leading to H3K27M expression occur in both canon-
ical H3.1 and H3.2 as well as in histone variant H3.3,
whereas mutations leading to expression of H3K36 and
H3G34 occur only in H3.3 (Table 2). The functional im-
portance of the preferential prevalence of mutations in
histone variants is not clear, and it would be interesting
to test whether mutations in H3.1 leading to the expres-
sion of K36 and G34 have effects similar to those of muta-
tions in H3.3, which has been shown for H3K27M (Chan
et al. 2013; Lewis et al. 2013; Mohammad et al. 2017).
In vitro studies have shown that, similar to K27M and
K36Mmutations, themethionine substitution at other ly-
sine residues (e.g. K9 and K4) in the H3 tail affects the
globalmethylation levels of the associated residues (Lewis
et al. 2013). While this observation could suggest that
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mutants of these residues contribute to tumorigenesis, no
suchmutations have been identified in disease. Theymay
be infrequent or exist only in rare tumors, and it will be ex-
citing to see whether such mutations will be identified.
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